5-Amino-1MQ for weight loss: bold claims, thin human data

What's this video probably claiming?

Based on the caption, this creator is pitching 5-Amino-1MQ as a metabolic optimizer that works differently from conventional weight loss drugs. The framing, "unlike traditional weight loss drugs that often suppress appetite," is a classic setup for positioning an unproven compound as somehow cleaner or smarter than FDA-approved options. The biohacking and functional medicine angle suggests the video likely claims 5-Amino-1MQ boosts metabolism by inhibiting an enzyme called NNMT (nicotinamide N-methyltransferase), improves body composition without caloric restriction, and may enhance athletic performance. Expect language about "cellular energy," possibly NAD+ pathways, and mitochondrial function. The peptide category tag is technically a mislabel since 5-Amino-1MQ is a small molecule, not a peptide, which tells you something about how loosely these compounds get lumped together in the wellness content ecosystem.

What does the science actually show?

The honest answer: almost nothing in humans. The foundational research on NNMT inhibition comes from Neelakantan et al. (2019, Nature Communications), which showed that a related NNMT inhibitor reduced adiposity and improved metabolic markers in diet-induced obese mice. That is a mouse study. A follow-up from the same research group demonstrated that NNMT inhibition increased energy expenditure and reduced white adipose tissue in rodent models, but again, no human trials. 5-Amino-1MQ specifically has been discussed in preclinical contexts, including work cited by Migaud and colleagues, but peer-reviewed human pharmacokinetic or efficacy data for this specific compound is essentially nonexistent in indexed literature. The mechanistic story, that NNMT inhibition raises SAM (S-adenosylmethionine) availability and shifts adipocytes toward a more metabolically active state, is biologically plausible. Plausible is not the same as proven.

Where does the social media noise diverge from clinical reality?

The gap here is enormous. TikTok and biohacking forums treat mouse-model findings as if they translate directly to human outcomes, which is a failure mode that has burned people repeatedly in drug development. Most compounds that look spectacular in rodent obesity models do not survive human trials, and NNMT inhibitors have not yet had that reckoning because the trials largely have not happened. The performance enhancement angle is even murkier. There is no indexed clinical data linking 5-Amino-1MQ to measurable improvements in VO2 max, power output, or recovery in humans. Dosing information circulating online, often in the range of 50-100mg per day, is extrapolated from animal studies with no validated human dose-response curve. Long-term safety data is absent. The compound is not FDA-approved, not FDA-cleared, and is sold through compounding pharmacies and gray-market research chemical suppliers with zero standardized quality control.

What should you actually know?

5-Amino-1MQ is a research compound with an interesting mechanistic rationale and genuinely zero clinical trial evidence for efficacy or safety in humans. That is not a minor caveat. People using this are essentially running uncontrolled experiments on themselves with no data on what happens past a few weeks of use. NNMT plays roles in inflammation, cancer biology, and epigenetic regulation, which means its inhibition carries theoretical risks that have not been characterized in humans at all. Comparing this to GLP-1 receptor agonists, which have decades of cardiovascular and metabolic outcome data, is not a fair comparison. If you are on a regulated telehealth platform, a provider recommending 5-Amino-1MQ for weight loss is operating well outside evidence-based medicine. The correct framing is that this is a preclinical compound under investigation, not a validated treatment. Anyone claiming otherwise is marketing, not practicing medicine.